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Abstract: Introduction: The precise time of using percutaneous coronary intervention (PCI) after fibrinolytic therapy for
maximum efficiency and minimum side effects is still undetermined. Therefore, the present study was designed
to compare the outcome of myocardial infarction (MI) patients who underwent surgical intervention (angiogra-
phy and PCI) within 48 hours of thrombolytic therapy or after that. Methods: The present study is a prospective
cohort study aiming to compare the occurrence of no-reflow phenomenon, unstable angina, bleeding during
intervention, and one month major adverse cardiac outcomes (recurrent MI, need for repeating surgical inter-
vention, and mortality) between MI patents undergoing surgical intervention within the first 48 hours of or after
48 hours of thrombolytic therapy. Results: 90 patients with the mean age of 54.97 ± 10.54 were studied (86.67%
male). 50 (56%) patients underwent surgical intervention within 48 hours and 40 (44%) after that. The 2 groups
were not significantly different regarding baseline characteristics. No-reflow phenomenon in the < 48 hours
group was about twice the > 48 hours group (OR = 0.35; 95% confidence interval: 0.14 – 0.92; p = 0.03), other
outcomes were not significantly different. No case of mortality was seen in the 1 month follow up. Conclusion:
Based on the results of the present study, it seems that no-reflow phenomenon rate is significantly lower in pa-
tients undergoing surgical intervention after 48 hours of fibrinolytic therapy. The difference between the two
groups regarding prevalence of major adverse cardiac outcomes was not statistically significant.
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1. Introduction
C
oronary artery disease (CAD) and its associated side
effects are the most common cause of mortality and
disability all over the world and its cost burden is the
highest among health care costs (1, 2). Currently, each year
900 thousand people are affected with acute myocardial in-
farction (MI) in the United States, which brings about 225
thousand deaths(3). In the past, open-heart surgery was the
major treatment for CAD (4). Yet, in recent years, coronary
artery angioplasty through the skin has been proposed as an
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efficient treatment for ST elevation MI (STEMI)(5). Unfortu-
nately, many STEMI patients either visit hospitals where per-
cutaneous coronary intervention (PCI) is not available, or are
not referred to PCI centers in the time range suggested by
guidelines (6). In these cases, alternative treatment is using
fibrinolytic agents such as tissue plasminogen activator and
streptokinase. Although according to the most recent guide-
lines of American Heart Association (AHA), angiography and
PCI should be done within 3 to 24 hours of fibrinolytic ther-
apy, evidence presented in it are derived from level B and C
articles, which partially affects its reliability (6). Initial studies
have questioned effectiveness of PCI and early angiography
after fibrinolytic therapy (7, 8). Yet, the power of the studies
carried out in this regard are not high enough to confirm the
effectiveness of this treatment (5, 9-11). Consequently, the
precise time of using PCI after fibrinolytic therapy for max-
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imum efficiency and minimum side effects is still undeter-
mined. Therefore, the present study was designed to com-
pare the outcome of MI patients who underwent surgical in-
tervention (angiography and PCI) within 48 hours of throm-
bolytic therapy or after that.
2. Methods
2.1. Study design and setting
The present study is a prospective cohort study aiming to
compare the outcome of MI patients who underwent surgical
intervention (angiography and PCI) either within the first 48
hours of or after 48 hours of undergoing thrombolytic ther-
apy. The researchers adhered to the principles of Helsinki
Declaration throughout the study and the protocol of the
study was approved by the Ethical committee of Islamic Azad
University, Medical Sciences Branch.
2.2. Participants
Patients visiting the emergency department (ED) of Bouali
Hospital, Tehran, Iran, who were diagnosed with STEMI,
were evaluated. Patients over 18 years old, suffering from
STEMI, whose symptoms had initiated less than 12 hours
ago, and had successful thrombolytic therapy were included.
In contrast, those with underlying illnesses such as cancer,
chronic hepatic and renal failure (creatinine > 250 mmol/l);
pregnant women; drug and alcohol addicts; and those pro-
hibited from using fibrinolytic therapy were excluded. After
reaching diagnosis in ED, patients were sent to coronary care
unit (CCU), where they underwent thrombolytic therapy and
were scheduled for surgical intervention, based on patient
condition and preference of in charge cardiologist. Without
any interferences from the researches, the participants were
followed for 1 month regarding major adverse cardiac out-
comes. 1-month follow-up was done by phone calls or in-
person. After the follow-up period, patients were divided into
2 groups of < 48 hours and > 48 hours based on time inter-
val between thrombolytic therapy and surgical interventions,
and the surgical side effects and one month adverse cardiac
outcomes were compared between the 2 groups. The time
interval between initiation of fibrinolytic therapy and inter-
vention was 3 to 48 hours in <48 hours group.
2.3. Outcome
Patients were followed regarding no-reflow phenomenon,
unstable angina, and bleeding during intervention, as well
as one month major adverse cardiac outcomes including re-
current STEMI or non-ST elevation MI (NSTEMI), need for
repeating surgical intervention, and mortality.
2.4. Definitions
-Recurrent NSTEMI: presence of a Q wave in 2 or more adja-
cent electrocardiogram leads accompanied by a rise in crea-
tine kinase MB or troponin concentration to above the nor-
mal range and more than 50% of the previous measure 18
hours after surgical intervention.
- Recurrent STEMI: relapse of ischemia symptoms while rest-
ing, accompanied by ST elevation of at least 0.1 millivolt in
at least 2 adjacent electrocardiogram leads for more than 30
minutes during the first 18 hours after surgical intervention.
- Unstable angina: chest pain while resting, with or without
changes in electrocardiogram (ECG) and pain class (based
on the classification of Canadian Cardiovascular Society), or
presence of dangerous arrhythmias such as atrial tachycar-
dia and atrial fibrillation.
- No-reflow phenomenon: inadequate muscle perfusion
without angiographic evidence of obstruction in a myocar-
dial vessel (12). Severity of hemorrhage during intervention
was determined based on GUST (Global Use of Strategies to
Open coronary arteries) severity scale (13).
2.5. Statistical Analysis
Data were analyzed using SPSS version 20.0. Qualitative data
were presented as frequency and percentage and quantita-
tive ones as mean ± standard deviation. Student t-test was
used for comparing means and chi-square or Fisher’s exact
tests for comparing categorical variables. In all analyzes p <
0.05 was considered as significance level.
3. Results
90 patients with the mean age of 54.97 ± 10.54 were evalu-
ated (86.67% male). 50 (56%) patients underwent surgical
intervention within 48 hours and 40 (44%) after that. Table
1 compares the baseline characteristics of patients in the 2
groups. The 2 groups were not significantly different regard-
ing baseline characteristics. Table 2 compares the frequency
of outcomes in the groups, which showed a significant differ-
ence only regarding no-reflow phenomenon. This outcome
in the < 48 hours group was about twice the > 48 hours group
(p = 0.03). The odds ratio for occurrence of no-reflow phe-
nomenon in patients who underwent surgical intervention
after 48 hours of fibrinolytic therapy was significantly lower
(OR = 0.35; 95% confidence interval: 0.14 – 0.92; p = 0.03).
4. Discussion
The findings of this study showed that the frequency of ad-
verse outcomes between MI patients undergoing surgical in-
tervention (angiography and PCI) within the first 48 hours
and after 48 hours of receiving thrombolytic agents was not
significantly different except for no-reflow phenomenon. In
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Table 1: Baseline characteristics in the studied groups
Variable First 48 hours (%) After 48 hours (%) P
Total (n=50) Total (n=40)
Age (year) 55.5 ± 12.1 54.3 ± 10.9 0.63
Sex (Male) 43 (86.0) 35 (87.5) 0.84
Medical history of
Diabetes mellitus 17 (34.0) 14 (35.0) 0.92
Hypertension 22 (44.0) 14 (35.0) 0.39
Hyperlipidemia 20 (40.0) 14 (35.0) 0.63
Cardiovascular accident 7 (14.0) 5 (12.5) 0.84
Myocardial infarction 13 (26.0) 7 (17.5) 0.34
Smoking 25 (50.0) 24 (60.0) 0.4
∗ Data are presented as mean Âś standard deviation or number and percentage.
Table 2: Comparison of patient outcomes in the 2 groups
Complications First 48 hours (%) After 48 hours (%) P
Bleeding during intervention 1 (2) 0 (0.0) 0.56
No-Reflow phenomenon 22 (44) 9 (22.5) 0.03
One month adverse cardiac outcomes
Recurrent Myocardial infarction 1 (2) 0 (0.0) 0.56
Repeating revascularization 0 (0.0) 0 (0.0) —
Mortality 0 (0.0) 0 (0.0) —
other words, the odds of no-reflow phenomenon was signif-
icantly lower in patients who underwent surgical interven-
tion after 48 hours. Although the difference between other
studied outcomes was not statistically significant, both cases
of major adverse cardiac outcomes were seen in < 48 hours
group. No mortality was seen in the 1-month follow-up. In
the years before using stent, early PCI has not been efficient
and has been associated with side effects such as hemor-
rhage, mortality, and coronary artery re-occlusion (14, 15).
However, using stents has significantly decreased post-PCI
coronary artery re-occlusion incidence (16, 17). This has en-
couraged doing PCI immediately after fibrinolytic therapy (6,
18-20). As a result, the most recent guideline of AHA has
expressed that STEMI patients should undergo PCI as soon
as possible. In cases that the patient has undergone fibri-
nolytic therapy, the ideal time for doing PCI is within the first
24 hours, yet it should not be done in the first 2 – 3 hours
(6). In a trial, Armstrong et al. have expressed that early PCI
and angiography show better outcomes and fewer side ef-
fects compared to late PCI (21). Cantor et al. also believed
that early PCI is an efficient therapy with few side effects and
the smaller the time interval between fibrinolytic therapy and
PCI, the better the results (14). In contrast, the findings of
the present study showed that PCI and angiography in the
first 48 hours have more side effects compared to the sec-
ond 48 hours. In line with this study, Collet et al. in their
meta-analysis showed that patients who undergo early PCI
show more side effects compared to those who undergo in-
tervention after 24 or 48 hours (9). However, a study by Ed-
mond et al. showed that there is no difference between vari-
ous time intervals of PCI after fibrinolytic therapy, and results
and side effects are similar (22). A review article by Capo-
danno et al. revealed that pharmaco-invasive therapy is ef-
fective in STEMI treatment and its time does not make a dif-
ference in the outcome of treatment or side effects (23). Vant
Hof et al. did not detect a significant difference between early
and after 48 hours PCI (24). As can be seen, there is signifi-
cant difference between study results, which might be due
to differences in study design (cohort, clinical trial, or cross-
sectional), type of MI, type of thrombolytic used (streptoki-
nase or t-PA), and not paying attention to outcomes such as
no-reflow phenomenon. This variation in findings also re-
veals the need for further studies in this field.
5. Limitation
The power of the present study was low for comparing mor-
tality rate and other side effects, except for no-reflow phe-
nomenon between the two groups. 1-month follow-up done
in the present study only evaluates the short-term adverse
outcomes, while long-term follow-ups may enable more ac-
curate assessment. Long-term follow-up and designing fur-
ther interventional studies is suggested.
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6. Conclusion
Based on the results of the present study, it seems that no-
reflow phenomenon rate is significantly lower in patients un-
dergoing surgical intervention after 48 hours of fibrinolytic
therapy. The difference between the two groups regarding
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